international pharmaceutical compliance congress
international pharmaceutical compliance congress
international pharmaceutical compliance congress
international pharmaceutical compliance congress
international pharmaceutical compliance congress
international pharmaceutical compliance congress



Overview | Agenda | Promotional Opportunities | Continuing Education | Grantors & Exhibitors | Travel/Hotel
Registration | Speaking Proposals | Administration | Webcast Log In | Past Conferences | Contact Us | Home





EIGHTH INTERNATIONAL PHARMACEUTICAL COMPLIANCE CONGRESS

May 5 - 7, 2014

ATTEND ONSITE
WEBCAST ATTENDANCE
Conrad Dubai
Dubai, United Arab Emirates
In your own office or home live via the Internet with 24/7 access for 6 months



KEYNOTE SPEAKERS

Michel Ballieu
Chief Executive Officer, European CanCer Organisation, Brussels, Belgium

Isabel Bardinet
Chief Executive Officer, European Society of Cardiology, Sophia Antipolis, France

Richard Bergström
Director General, European Federation of the Pharmaceutical Industries and Associations (EFPIA), Former Director General, LIF Sweden, Brussels, Belgium

Julie Bonhomme, Esq.
Legal and Compliance Manager, Legal and Compliance Department, LEEM, Paris, France

Ingrid Callies, LLM, PhD
Permanent Secretary of the CODEEM (the ethics committee of the pharmaceutical industry), French Code Authority, Leem, Paris, France

Holger Diener, PhD
Managing Director, Association of Voluntary Self-Regulation for the Pharmaceutical Industry, Berlin, Germany

Debra Christenson Forster, Esq.
Global Compliance Officer, Novartis Pharma AG, Former Executive Director, Marketing and Sales Compliance, Boehringer Ingelheim, Basel, Switzerland

Jane Griffiths, PhD
Company Group Chairman Janssen, Europe, Middle East and Africa (EMEA), Janssen-Cilag Ltd., EMEA; Chairman, EFPIA Executive Committee; Chairman, PhRMA Europe Committee, Buckinghamshire, UK

Dr. Yacoub Haddad
Chair, Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG), Government Affairs Director MEAP Region, Abbvie, Dubai, UAE

Parichay Mittal
Director - Compliance, South Asia, Compliance & Business Integrity Department, Sanofi, Member, Working Group on Ethics and Compliance, Organization of Pharmaceutical Producers of India (OPPI), Mumbai, India

Arthur Muratyan, Esq.
Secretary General, International Society of HealthCare Ethics and Compliance Professionals (ETHICS), Former Vice President-Head of Legal Corporate, and Global Compliance Officer, Sanofi, Paris, France

Jean-Claude Najar, LLM
Member, Curtis, Mallet-Prevost, Colt & Mosle LLP, Lecturer, Sciences Po Law School and HEAD Law School, Former General Counsel EMEA, GE Medical Systems (now GE Healthcare), Paris, France

Prof. Dr. iur. Mark Pieth
Professor of Criminal Law and Criminology, University of Basel, Former Head of Section, Economic and Organised Crime, Swiss Federal Office of Justice, Former Chair, OECD Working Group on Bribery in International Business Transactions, Basel, Switzerland

Christine Sainvil
Compliance Officer, Eucomed, Brussels, Belgium

Heather Simmonds
Director and Chair, Code of Practice Panel, Prescription Medicines Code of Practice Authority, London, UK

Carin R. Smand, MSc
Managing Director, European Hematology Association, The Hague, The Netherlands

Peter Solmssen
Former General Counsel and Head of Legal and Compliance and Member, Managing Board, Siemens AG, Former General Counsel Germany and Lead Lawyer Commercial Finance Europe, General Electric Company, Munich, Germany

Jose F. Zamarriego Izquierdo
Director Unidad de Supervision Deontologica, FARMAINDUSTRIA, Madrid, Spain

THE CONGRESS FEATURES EU COMPLIANCE DEVELOPMENTS,
WITH SPECIAL REPORTS FROM CEE, MEA AND INDIA
FEATURING A FOCUS ON NEW PHARMA BUSINESS MODELS
AND RESULTING COMPLIANCE CHALLENGES
  • Changing Business Models:
    • Context:
      • Rising Costs
      • Decline of Blockbuster Model
      • Rise of Specialty Care/Biologics
    • Industry Trends:
      • Consolidation
      • Patent Cliff
      • Mature Markets
      • Growth of Emerging Markets
      • Diversification into Diagnostics and Devices, Generics and Consumer Health
      • More Partnerships, Collaborations, and Licensing Agreements
    • Old Model Centered on Company/HCP Relationship
    • New Model in US, ACA, Increased Governmental Funding and Negotiations with Insurers
    • New Model Globally, Negotiation with Government
    • Emerging of Comparative Effectiveness Research
  • New Ethics and Compliance Issues Arise around:
    • Market Access, Affordability, Infrastructure and Knowledge in Emerging Markets, Limiting Health Care Systems
    • Managing Third Party Relationships, Increased Risk, Less Transparency
    • Pricing and Reimbursement; Conditional upon Post Marketing Confirmation of Effectiveness
    • Tendering
    • R&D; Clinical Trials; Publications
    • Medical Education
    • New National Anticorruption Initiatives
    • Proliferation of Transparency Initiatives
    • The Role of Compliance Codes

FEATURING IFPMA CODE WORKSHOP AND ETHICAL PROMOTION ROUNDTABLE
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is offering an independent IFPMA CODE WORKSHOP: HANDS-ON COMPLIANCE TRIANING on Sunday, May 4, 2014.
Tamara Music, Manager, Influenza Vaccines & Code Compliance, IFPMA, Geneva, Switzerland (Chair)

A MIDDLE EAST/AFRICA (MEA) REGIONAL COMPLIANCE ROUNDTABLE
Sponsored by International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG)
On the morning of Monday, May 5, 2014 the following will co-chair a MEA Regional Compliance Roundtable:
Nabil Daoud, MA, Vice President and Area Director TMEA-CIS, Eli Lilly, Chair, MEA Regional Ethics Group (LERB), Dubai, United Arab Emirates
Dr. Yacoub Haddad, Chair, Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG), Government Affairs Director MEAP Region, Abbvie, Dubai, UAE

THE CONGRESS THE FOLLOWING PLENARY SESSIONS
  • Congress Vision and Overview
  • MEA Compliance Best Practices Overview
  • India Compliance Best Practices Overview
  • Global Transparency Regulatory Update Roundtable
  • Communicating with Health Care Professionals re Participation in Transparency Programs
  • The Perspectives of Leading NGOs re Pharma Ethical and Compliance Regimes
  • Medical Device Compliance and Ethics Issues Update
  • Emerging Compliance Issue: R&D, Clinical Trials, Post Marketing Studies and Publications
  • Emerging Compliance: Market Access, Pricing, Reimbursement and Tendering
  • Emerging Compliance Issue: Medical Education and the Thin Line between Information and Promotion
  • Roundtable on Current Challenges and New National Anticorruption Initiatives
  • The Role of Ethics in the Compliance Decision Making Process
  • The Worldwide Enforcement Environment for Pharma and Medical Devices
  • Transforming the Compliance Profession
  • Global Compliance Code Update

AND THE FOLLOWING IN-DEPTH
MINI SUMMITS
  • Training on Compliance and Ethics Basics I
  • Annual MEA Compliance and Ethics Update
  • Global Compliance Auditing and Monitoring Best Practices
  • R&D, Clinical Trials, Transparency, Post Marketing Studies and Publications
  • Advanced Issues in Global Transparency , Disclosure and Aggregate Spend Compliance
  • Training on Compliance and Ethics Basics II
  • Indian Compliance Best Practices Roundtable
  • Medical Education and the Thin Line between Information and Promotion
  • Global Fair Market Value Update
  • Congresses and the Realities of Cross-border Confluence
  • Training on Compliance and Ethics Basics III
  • Annual Central and Eastern Europe Compliance Update
  • Lessons from the Global Medical Device Sector Compliance Issues
  • Advanced Issues in Global Anticorruption Compliance
  • Public Procurement, Tendering, Reimbursement and Pricing Update
  • Managing the Compliance Function being both Small and Global
  • Turkish Compliance Roundtable
  • Using Data Analytics and Going Beyond Policy Compliance
  • The Business Benefits of Compliance

FEATURED FACULTY

Ted Acosta, Esq.
Principal, Fraud Investigation & Dispute Services, EY; Former Senior Counsel, Office of Inspector General, United States Department of Health and Human Services, New York, NY, USA and Paris, France

Dr. Amin Al Amiri
Assistant Undersecretary, Medical Practice and Licenses, Ministry of Health, UAE, Dubai, UAE

Timothy S. Ayers, Esq.
Principal, Porzio, Bromberg & Newman, PC, Vice President, Porzio Life Sciences, Former Vice President and Chief Compliance Officer, Dendreon Corporation, Morristown, NJ, USA

Yogesh Bahl, MBA
Life Sciences Practice Lead, Financial Advisory Services, AlixPartners, LLP, New York, NY

Hulya Baran
Director, Ethics and Compliance TMEA - CIS, Eli Lilly and Company, Istanbul, Turkey

Bulent Becan
Managing Partner, Atuva Management Consultancy and Trade Ltd., Consultant in Ethics Issues, Turkish Research Based Pharmaceutical Companies Association (AIFD), Istanbul, Turkey

Carsten Blaesberg
Chief Consultant, Lif Denmark, The Danish Association of the Pharmaceutical Industry, Copenhagen, Denmark

Hein van den Bos, Esq.
Counsel, Hogan Lovells International LLP, Amsterdam, Netherlands

Rifat Bozacioglu
Deputy Compliance Officer, Compliance Business Partner, MEA Pharma Compliance, GlaxoSmithKline, Istanbul, Turkey

Karl Buch, Esq.
Assistant General Counsel, Pfizer, New York, NY, USA

Kris L. Curry
Principal, Fraud Investigation & Dispute Services, EY, Philadelphia, PA, USA

Nabil Daoud, MA
Vice President and Area Director TMEA-CIS, Eli Lilly, Chair, MEA Regional Ethics Group (LERB), Dubai, United Arab Emirates

Sacha D'Ecclesiis, Esq.
Senior Associate, Hogan Lovells, Rome, Italy

Peter Dieners, Esq.
Partner, Clifford Chance, Düsseldorf, Germany

Sue Egan
Director and Principal Consultant, Sue Egan Associates, Former Vice President Compliance, AstraZeneca, Great Missenden, Buckinghamshire, UK

Walid Fahim
Regional Compliance Manager, Turkey, South Africa & Middle East, EMEA, Emerging Markets, Covidien, Dubai, United Arab Emirates

Saad Fahmy
Compliance Director, Middle East & Pakistan, Sanofi, Former Compliance Officer (Gulf, Saudi, Arabia & Developing Markets), Merck, Dubai, United Arab Emirates

Pascale Feghali
Ethics & Compliance Director, Middle East & Egypt, Eli Lilly, Beirut, Lebanon

George Fife
Executive Director, EMEA Compliance & Ethics, Bristol-Myers Squibb, Paris, France

Gary F. Giampetruzzi, Esq.
Partner, Paul Hastings; Former Vice President and Assistant General Counsel and Head of Government Investigations, Pfizer Inc., New York, NY, USA

Ulf Grundmann, JD
Partner, King & Spalding, Lecturer, Frankfurt School of Finance and Management and Deutsche Anwalts Akademie, Author, Guide to EU Pharmaceutical Regulatory Law, Frankfurt, Germany

Meltem Ozker Gunduz
Legal Affairs and Compliance Director, Business Area Near East, Novo Nordisk, Istanbul, Turkey

Thomas A. Gunning, Esq.
Senior Vice President and General Counsel, Prescription Medicines' Division, Merck KGaA, Darmstadt, Germany

Antoinette Gutierrez-Crespin
Partner, Fraud Investigation & Dispute Services, EY, Paris, France

Rozalia Gyulai
Regional Compliance Manager, AbbVie, Former Regulatory Manager, Pfizer, Budapest, Hungary

Tareq Haddad
Regional Strategic Planning Manager, PwC, United Arab Emirates

Joe Henein
President and Chief Executive Officer, NewBridge Pharmaceuticals, Former Regional Managing Director, Middle East, and North Africa, Wyeth Pharmaceuticals, Dubai, United Arab Emirates

Sally Jeffery, MBA
Partner, PwC, Dubai, UAE

Swee Kheng Khor, MD
Associate Director, Office of Ethics & Compliance, Middle East & Pakistan, AbbVie BioPharmaceutical, GmBH, Dubai, United Arab Emirates

Dr. Marcel Koerting, LLM
Senior Legal & Compliance Counsel, Novo Nordisk Health Care AG, Zurich, Switzerland

Keith M. Korenchuk, JD, MPH
Partner, Arnold & Porter LLP, Washington, DC, USA

Daniel A. Kracov, Esq.
Partner and Head, FDA and Healthcare Practice, Arnold & Porter, Washington, DC, USA

Michael K. Loucks, Esq.
Partner, Skadden Arps LLP, Former Acting United States Attorney, District of Massachusetts, Washington, DC, USA

Abdul Luheshi, MBA
Vice President Health Care Compliance, Asia Pacific, Johnson & Johnson, Former Co-chair, Asia Pacific Pharma Compliance Congress, Singapore

Rajiv Malhotra
Senior Manager Compliance, Biogen Idec, Former Ethics and Compliance Officer, Eli Lilly and Company (India) Pvt Ltd, Gurgaon, India

Paul J. Melling, Esq.
Founding Partner, Baker & McKenzie - CIS, Limited, Moscow, Russia

Laura Nassar
Regional Pharma HCC Officer Emerging Markets, Johnson & Johnson, Beirut, Lebanon

Dr. Ima Parrondo
Health Care Compliance Lead Officer Pharmaceuticals, EMEA-C, HCC&P, Johnson & Johnson, Madrid, Spain




Minal Patel
Compliance Officer, Pharmaceuticals & Consumer, South Africa & Sub Saharan Africa, Johnson & Johnson, Johannesburg, South Africa

Piergiorgio Pepe, LLB, LLM
Office of Ethics & Compliance Regional Director, Eastern Europe-Middle East & Africa, Abbvie Pharmaceuticals Europe HQ, Rungis, France

Dr. Gudula Petersen
Chief Compliance Officer Europe & Australia, Grunenthal, Aachen, Germany

Nathalie Raynaud
Corporate Compliance Director, Global Compliance & Business Integrity Department, Sanofi, Paris, France

Brian Riewerts
Principal, Global Governance, Risk and Compliance Leader, Pharmaceutical and Life Sciences Advisory, PwC, Baltimore, MD, USA

Vivian Robinson, Esq.
Partner, McGuire Woods, Former General Counsel of the UK Serious Fraud Office, Former Head, QEB Hollis Whiteman Chambers, Recorder of the Crown Court and Treasurer of Inner Temple, London, UK

Jeff Rosenbaum
Vice President, Chief Compliance Officer, Vertex Pharmaceuticals, Former Executive Director, Global Head of Ethics & Compliance Novartis Oncology, Boston, MA, USA

Christian-Claus Roth
Head of Congresses and Conventions, Novartis Pharma, Co-President, International Pharmaceutical Congress Advisory Association (IPCAA), Berne, Switzerland

Fabien Roy
Associate, Hogan Lovells, Brussels, Belgium

Sandeep Seth, LLB
Director - Compliance, MSD Pharmaceuticals Pvt. Ltd. (Merck), Mumbai, India

Jade L. Shields
Chief Compliance Officer and Associate Vice President, Ferring Pharmaceuticals, Parsippany, NJ, USA

Abdulrahman Al Sultan
Executive Director of Communication & Awareness, Saudi Food & Drug Authority, Riyadh, Saudi Arabia

Tahan (Tom) A. Thraya, Esq.
Partner, Baker & McKenzie LLP, Abu Dhabi, UAE

Joseph B. Tompkins, Jr.
Partner, Sidley Austin LLP, Former Deputy Chief of the Fraud Section, Criminal Division, United States Department of Justice, Washington, DC, USA

Magalie Treguer, Esq.
Senior Director, Corporate Compliance and Regional Compliance Officer for Europe and Canada, Biogen Idec, International GmbH, Zürich, Switzerland

Ramesh Varadarajan
Local Compliance Officer, AstraZeneca Pharma India Ltd., Bangalore, India

Vincent M. Walden, CFE, CITP
Partner, Fraud Investigation & Dispute Services, EY, New York, NY, USA

Mariusz Witalis, CFE, CIA
Partner, Fraud Investigation & Dispute Services, EY, Warsaw, Poland

David Wysocky, MBA
Partner, PwC, New York, NY



BROCHURE NOW AVAILABLE
Click here to download
the brochure.
ASSOCIATION REGISTRATION DISCOUNT
Click here for Special ETHICS/PCF/IFPMA/EFPIA/ PhRMAG/OPPI/USIBC Member Rate.


SPONSORED BY:



CO-SPONSORED BY:



CONGRESS CO CHAIRS

Ann Beasley Bacon
Senior Vice President and Chief Compliance Officer, Biogen Idec, Board Member and Co-chair, Strategic Committee, International Society of Healthcare, Ethics and Compliance Professionals (ethics), Cambridge, MA, USA

Dr. Michael Bartke
Director Compliance Management, DAIICHI SANKYO EUROPE GmbH, Co-chair, EFPIA Compliance Workgroup, Munich, Germany

Dominique Laymand
Vice President Compliance & Ethics EMEA, (Europe, Middle-East, Africa, Russia and Turkey), Bristol-Myers Squibb, President, International Society of Healthcare, Ethics and Compliance Professionals (ethics), Paris, France

Roeland Van Aelst
Vice President Health Care Compliance Medical Devices & Diagnostics EMEA-C, HCC&P, Johnson & Johnson, Board Member and Co-chair, Strategic Committee, International Society of Healthcare, Ethics and Compliance Professionals (ethics), Chairman, EUCOMED Compliance Network, Brussels, Belgium
MEDIA PARTNER


OUTREACH PARTNER



CONTINUING EDUCATION CREDITS
Compliance Professionals: Approved for up to 18.4 Compliance Certification Board CCB Credits.

Accounting Professionals: Approved for up to 19 NASBE CPE credits.

Attorneys:
  • Approved to offer a maximum of 15 Hours of Pennsylvania CLE Credits, including 2.0 Hours for Ethics CLE.
  • Approved to offer a maximum of 16.0 Hours of Texas CLE Credits.
  • The Congress is currently pending approval to offer California MCLE Credit.
Click here for more information.

GRANTORS:
DIAMOND


PLATINUM


GOLD


BRONZE
























FEATURING VIDEO PRESENTATIONS FROM PAST CONGRESSES:
2013 Seventh International Pharma Congress Keynote Address by

Huguette Labelle, CC, PhD, LLD
Chair, Transparency International, Companion of the Order of Canada, Berlin, Germany
2013 Fourteenth International US Pharma Congress Keynote Address by

Brent L. Saunders, JD, MBA
Chief Executive Officer, Forest Laboratories, Former Chief Executive Officer, Bausch + Lomb, Rochester, NY
2012 Second Asia Pacific Pharma Congress Keynote Address by

Mark Mallon, MBA
Regional Vice President Asia Pacific and President China, AstraZeneca, Former Executive Vice-President and Chief Operating Officer, AstraZeneca KK (Japan), Shanghai, China
2012 Sixth International Pharma Congress Keynote Address by

Christopher A. Viehbacher
Chief Executive Officer, Sanofi, Chairman, Genzyme, Paris, France
2011 Twelfth Pharmaceutical Regulatory Compliance Congress and Best Practices Forum by

John C. Lechleiter, PhD
Chairman, President and Chief Executive Officer, Eli Lilly and Company, Chairman-elect, PhRMA, Indianapolis, IN

2011 Fifth International Pharma Congress Keynote Address by

David Brennan
Former Chief Executive Officer, AstraZeneca, President, IFPMA, Past Chairman, PhRMA, London, UK

OTHER INTERNATIONAL PHARMA CONGRESSES

2007 - Brussels


2008 - Paris


2009 - Rome


2010 - Berlin


2011 - Istanbul


2011 - Singapore


2012 - Budapest


2012 - Shanghai


2012 - São Paulo


2013 - Madrid, Spain


2013 - Kuala Lumpur


2014 - Dubai


2014 - Mexico City

FOLLOW INTERNATIONAL PHARMA CONGRESS ON




INTERNATIONAL PHARMA CONGRESS IS



SAVE THE DATES

SECOND LATIN AMERICAN PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS
A Hybrid Conference and Internet Event
Sponsored by Latin American Ethics and Compliance Network
Cosponsored by International Society of Healthcare Compliance Professionals (ETHICS) and Pharmaceutical Compliance Forum (PCF)
July 28 - 31, 2014
Mexico City, Mexico
www.LatinAmericanPharmaCongress.com
FOURTH ASIA PACIFIC PHARMACEUTICAL
COMPLIANCE CONGRESS

A Hybrid Conference and Internet Event
Sponsored by Asia Pacific Healthcare Industry Compliance Team
Cosponsored by International Society of Healthcare Ethics and Compliance Professionals (ETHICS) and Pharmaceutical Compliance Forum (PCF)
September, 2014
Beijing, China
www.AsianPharmaCongress.com
FIFTEENTH PHARMACEUTICAL REGULATORY
AND COMPLIANCE CONGRESS

A Hybrid Conference and Internet Event
Transformational Learning - Effective Knowledge Exchange
Sponsored by Pharmaceutical Compliance Forum
November 3 - 5, 2014
Hyatt Regency on Capitol Hill
Washington, DC
www.PharmaCongress.com

NEW PARTICIPATION OPTION: LIVE AND ARCHIVED INTERNET ATTENDANCE
Announcing a new way to participate in the International Pharma Congress: You can now register to watch the Congress in live streaming video over the Internet and at your convenience at any time 24/7 for the six months following the event.
TRADITIONAL ONSITE ATTENDANCE
Simply register, travel to the conference city and attend in person.

Pros: subject matter immersion; professional networking opportunities; faculty interaction





We subscribe to the HONcode principles of the HON Foundation. Click to verify.




LIVE AND ARCHIVED WEBCAST ATTENDANCE
Watch the conference in live streaming video of plenary sessions and listen to audio of preconference and track sessions over the Internet and at your convenience at any time 24/7 for six months following the event.

The archived conference includes speaker Video and Audio and coordinated PowerPoint presentations.

Pros: Live digital feed and 24/7 Internet access for the next six months; accessible in the office, at home or anywhere worldwide with Internet access; avoid travel expense and hassle; no time away from the office.





WEBCAST INTERFACE SAMPLE

Click here for a sample stream

THE 2013 SEVENTH INTERNATIONAL PHARMA CONGRESS CONTENT IS NOW AVAILABLE
IN VARIOUS POST CONFERENCE FORMATS

The 2013 Seventh International Pharma Congress conference content is now available in a variety of formats.

You may purchase the Congress streaming content in the following formats: Flash Drive or online archive (6 months). You may also purchase individual presentations in an online archive (6 months) format.

YOU CAN PURCHASE JUST THE INTERNATIONAL PHARMA CONGRESS CONTENT AS FOLLOWS:

Online Archive of 2013 Seventh International Pharma Congress Presentations today!
Complete conference: $595
Order Now

Flash Drive of 2013 Seventh International Pharma Congress Presentations today!
$595
Order Now

FINALLY YOU MAY PURCHASE INTERNATIONAL PHARMA CONGRESS INDIVIDUAL PRESENTATIONS:
Click here to purchase individual presentations for $59.95 in online archive format (6 months of access - 24/7).





Overview | Agenda | Promotional Opportunities | Continuing Education | Grantors & Exhibitors | Travel/Hotel
Registration | Speaking Proposals | Administration | Webcast Log In | Past Conferences | Contact Us | Home




© Health Care Conference Administrators
Contact Webmaster